The company said net sales for Q4 rose 4.3% to $2.023 billion (4.9% on a constant currency basis), and full-year net sales rose 3.8% to $7.679 billion (4.8% on a constant currency basis).

1. 01

   The company said net sales for Q4 rose 4.3% to $2.023 billion (4.9% on a constant currency basis), and full-year net sales rose 3.8% to $7.679 billion (4.8% on a constant currency basis).

2. 02

   The company said diluted earnings per share for Q4 were $1.20, and adjusted diluted earnings per share were $2.31. It said full-year diluted earnings per share were $4.43, and adjusted diluted earnings per share were $8.00.

3. 03

   Zimmer Biomet said full-year net cash provided by operating activities was $1,499.4 million ($1,581.6 million a year earlier), and free cash flow was $1,055.3 million ($978.8 million a year earlier). It said full-year share repurchases totaled $868.0 million, and dividend payments were $196.0 million.

4. 04

   The company gave its full-year 2025 outlook, with reported revenue change of 1.0% to 3.5%, constant currency revenue change of 3.0% to 5.0%, and adjusted diluted EPS of $8.15 to $8.35.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.